Perspective Therapeutics (CATX) Enterprise Value (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Enterprise Value data on file, last reported at -$487.9 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 28.72% year-over-year to -$487.9 million; the trailing twelve-month figure through Mar 2026 stood at -$487.9 million (down 28.72% YoY), and the FY2025 full-year result was -$144.7 million, up 36.22% from the prior year.
• Enterprise Value retreated to -$487.9 million in Q1 2026, from -$144.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$9.2 million in Q4 2023 to a low of -$487.9 million in Q1 2026.
• A 5-year average of -$167.9 million and a median of -$144.7 million in 2025 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value surged 78.89% in 2023 and sank 2356.33% in 2024, its largest moves.
• Tracing CATX's Enterprise Value over 5 years: stood at -$43.8 million in 2022, then surged by 78.89% to -$9.2 million in 2023, then slumped by 2356.33% to -$226.9 million in 2024, then jumped by 36.22% to -$144.7 million in 2025, then slumped by 237.06% to -$487.9 million in 2026.
• Business Quant data shows CATX's Enterprise Value at -$487.9 million in Q1 2026, -$144.7 million in Q4 2025, and -$174.1 million in Q3 2025.